Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 4, 2013, Pages 557-564

  De Aguiar Cordeiro, R ^a   Mourao C I ^a   Rocha, M F G ^a,b   De Farias Marques, F J ^a   Teixeira, C E C ^a   De Oliveira Miranda, D F ^a   Neto, L V P ^a   Brilhante, R S N ^a   De Jesus Pinheiro Gomes Bandeira, T ^a   Sidrim, J J C ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b STATE UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; COTRIMOXAZOLE; ERGOSTEROL; FOLIC ACID ANTAGONIST; PYRIMETHAMINE SULFADIAZINE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; BROTH DILUTION; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FUNGAL STRAIN; FUNGUS GROWTH; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DRUG COMBINATIONS; ENVIRONMENTAL MICROBIOLOGY; FOLIC ACID ANTAGONISTS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMETHAMINE; SULFADOXINE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84879464327     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1774-8     Document Type: Article

References (34)

1. Lin X, Heitman J (2006) The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol 60:69-105 (Pubitemid 44627941)
2. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50(3):291-322
3. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23(4):525-530
4. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363(9423):1764-1767 (Pubitemid 38698379)
5. Varma A, Kwon-Chung KJ (2010) Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother 54(6):2303-2311
6. Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M (2005) Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56(6):1144-1147 (Pubitemid 43009837)
7. Bii CC, Makimura K, Abe S, Taguchi H, Mugasia OM, Revathi G, Wamae NC, Kamiya S (2007) Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 50(1):25-30 (Pubitemid 46046416)
8. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ (2009) Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother 53(7):2804-2815
9. Martinez LR, Mihu MR, Han G, Frases S, Cordero RJ, Casadevall A, Friedman AJ, Friedman JM, Nosanchuk JD (2010) The use of chitosan to damage Cryptococcus neoformans biofilms. Biomaterials 31(4):669-679
10. Steverding D, Evans P, Msika L, Riley B, Wallington J, Schelenz S (2012) In vitro antifungal activity of DNA topoisomerase inhibitors. Med Mycol 50(3):333-336
11. Verwer PE, Woodle MC, Boekhout T, Hagen F, Bakker-Woudenberg IA, van de Sande WW (2011) Cryptococcus and Trichosporon spp. are susceptible in vitro to branched histidine- and lysine-rich peptides (BHKPs). J Antimicrob Chemother 66(7):1649-1652
12. Martinez LR, Casadevall A (2007) Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl Environ Microbiol 73(14):4592-4601 (Pubitemid 47122604)
13. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J (2009) Our current understanding of fungal biofilms. Crit Rev Microbiol 35(4):340-355
14. Martinez LR, Casadevall A (2006) Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect Immun 74(11):6118-6123 (Pubitemid 44657390)
15. Martinez LR, Casadevall A (2006) Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 50(3):1021-1033 (Pubitemid 43327808)
16. Robertson EJ, Wolf JM, Casadevall A (2012) EDTA inhibits biofilm formation, extracellular vesicular secretion, and shedding of the capsular polysaccharide glucuronoxylomannan by Cryptococcus neoformans. Appl Environ Microbiol 78(22):7977-7984
17. Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M (1986) Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiological study. Neurosurgery 18(3):373-375 (Pubitemid 16139400)
18. Ingram CW, Haywood HB 3rd, Morris VM, Allen RL, Perfect JR (1993) Cryptococcal ventricular-peritoneal shunt infection: clinical and epidemiological evaluation of two closely associated cases. Infect Control Hosp Epidemiol 14(12):719-722
19. Banerjee U, Gupta K, Venugopal P (1997) A case of prosthetic valve endocarditis caused by Cryptococcus neoformans var. neoformans. J Med Vet Mycol 35(2):139-141 (Pubitemid 27174587)
20. Johannsson B, Callaghan JJ (2009) Prosthetic hip infection due to Cryptococcus neoformans: case report. Diagn Microbiol Infect Dis 64(1):76-79
21. Cordeiro RA, Costa AK, Brilhante RS, de Lima RA, Castelo-Branco Dde S, Ribeiro JF, Monteiro AJ, Rocha FA, Sidrim JJ, Rocha MF (2011) PCR-REA as an important tool for the identification of Cryptococcus neoformans and Cryptococcus gattii from human and veterinary sources. Vet Microbiol 154(1-2):180-184
22. Enache-Angoulvant A, Chandenier J, Symoens F, Lacube P, Bolognini J, Douchet C, Poirot JL, Hennequin C (2007) Molecular identification of Cryptococcus neoformans serotypes. J Clin Microbiol 45(4):1261-1265 (Pubitemid 46626495)
23. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E; IberoAmerican Cryptococcal Study Group (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9(2):189-195 (Pubitemid 36231789)
24. Hanafy A, Uno J, Mitani H, Kang Y, Mikami Y (2007) In vitro antifungal activities of sulfa drugs against clinical isolates of Aspergillus and Cryptococcus species. Jpn J Med Mycol 48(1):47-50 (Pubitemid 46280134)
25. Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - third edition. CLSI document M27-A3. CLSI, Wayne, PA
26. Cordeiro Rde A, Astete-Medrano DJ, Marques FJ, Andrade HT, Perdigão Neto LV, Tavares JL, de Lima RA, Patoilo KK, Monteiro AJ, Brilhante RS, Rocha MF, de Camargo ZP, Sidrim JJ (2011) Cotrimoxazole enhances the in vitro susceptibility of Coccidioides posadasii to antifungals. Mem Inst Oswaldo Cruz 106(8):1045-1048
27. Costa AK, Sidrim JJ, Cordeiro RA, Brilhante RS, Monteiro AJ, Rocha MF (2010) Urban pigeons (Columba livia) as a potential source of pathogenic yeasts: a focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. Mycopathologia 169(3):207-213
28. Moran GP, Pinjon E, Coleman DC, Sullivan DJ (2007) Analysis of drug resistance in pathogenic fungi. In: Kavanagh K (ed) Medical mycology: cellular and molecular techniques. Wiley, Hoboken, pp 93-113
29. Peeters E, Nelis HJ, Coenye T (2008) Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 72(2):157-165
30. Navarro-Martínez MD, Cabezas-Herrera J, Rodríguez- López JN (2006) Antifolates as antimycotics? Connection between the folic acid cycle and the ergosterol biosynthesis pathway in Candida albicans. Int J Antimicrob Agents 28(6):560-567 (Pubitemid 44779175)
31. Hahn RC, Morato Conceição YT, Santos NL, Ferreira JF, Hamdan JS (2003) Disseminated paracoccidioidomycosis: correlation between clinical and in vitro resistance to ketoconazole and trimethoprim sulphamethoxazole. Mycoses 46(8):342-347 (Pubitemid 37204514)
32. Brilhante RS, Fechine MA, Cordeiro Rde A, Rocha MF, Ribeiro JF, Monteiro AJ, de Lima RA, Mesquita JR, de Camargo ZP, Sidrim JJ (2010) In vitro effect of sulfamethoxazole-trimethoprim against Histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother 54(9):3978-3979
33. Lim PL, Zhou J, Ditangco RA, Law MG, Sirisanthana T, Kumarasamy N, Chen YM, Phanuphak P, Lee CK, Saphonn V, Oka S, Zhang F, Choi JY, Pujari S, Kamarulzaman A, Li PC, Merati TP, Yunihastuti E, Messerschmidt L, Sungkanuparph S; TREAT Asia HIV Observational Database (2012) Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc 15:1
34. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ (2005) In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 43(8):3807-3810 (Pubitemid 41129665) Development Development